Expanding access to CAR T cell therapies through local manufacturing
M Elsallab, MV Maus - Nature biotechnology, 2023 - nature.com
Chimeric antigen receptor (CAR) T cells are changing the therapeutic landscape for
hematological malignancies. To date, all six CAR T cell products approved by the US Food …
hematological malignancies. To date, all six CAR T cell products approved by the US Food …
Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation
AN Khan, A Chowdhury, A Karulkar… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor T cell (CAR-T) therapy demonstrated remarkable success in long-
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
term remission of cancers and other autoimmune diseases. Currently, six products (Kymriah …
[HTML][HTML] Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
I Christodoulou, WJ Ho, A Marple… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background The prognosis of patients with recurrent/refractory acute myelogenous leukemia
(AML) remains poor and cell-based immunotherapies hold promise to improve outcomes …
(AML) remains poor and cell-based immunotherapies hold promise to improve outcomes …
A roadmap for affordable genetic medicines
M Kliegman, M Zaghlula, S Abrahamson, JH Esensten… - Nature, 2024 - nature.com
Twenty genetic therapies have been approved by the US Food and Drug Administration to
date, a number that now includes the first CRISPR genome-editing therapy for sickle cell …
date, a number that now includes the first CRISPR genome-editing therapy for sickle cell …
Optimal planning of the COVID-19 vaccine supply chain
GP Georgiadis, MC Georgiadis - Vaccine, 2021 - Elsevier
This work presents a novel framework to simultaneously address the optimal planning of
COVID-19 vaccine supply chains and the optimal planning of daily vaccinations in the …
COVID-19 vaccine supply chains and the optimal planning of daily vaccinations in the …
Chimeric antigen receptor-engineered natural killer (CAR NK) cells in cancer treatment; recent advances and future prospects
Natural Killer (NK) cells are critical members of the innate immunity lymphocytes and have a
critical role in host defense against malignant cells. Adoptive cell therapy (ACT) using …
critical role in host defense against malignant cells. Adoptive cell therapy (ACT) using …
Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells
Chimeric antigen receptor (CAR) T‐cell therapy has brought a paradigm shift in the
management of haematological malignancies and has opened novel avenues of …
management of haematological malignancies and has opened novel avenues of …
Development of CAR-T cell therapies for multiple myeloma
N Gagelmann, K Riecken, C Wolschke, C Berger… - Leukemia, 2020 - nature.com
Currently available data on chimeric antigen receptor (CAR)-T cell therapy has
demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) …
demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) …
Delivery of plasmid DNA by ionizable lipid nanoparticles to induce CAR expression in T cells
PHDM Prazeres, H Ferreira, PAC Costa… - International Journal …, 2023 - Taylor & Francis
Introduction Chimeric antigen receptor (CAR) cell therapy represents a hallmark in cancer
immunotherapy, with significant clinical results in the treatment of hematological tumors …
immunotherapy, with significant clinical results in the treatment of hematological tumors …
Emerging challenges and opportunities in pharmaceutical manufacturing and distribution
The rise of personalised and highly complex drug product profiles necessitates significant
advancements in pharmaceutical manufacturing and distribution. Efforts to develop more …
advancements in pharmaceutical manufacturing and distribution. Efforts to develop more …